Biotechnology company developing in vivo cellular reprogramming therapies to restore cell types lost through disease or injury
Biotechnology company developing in vivo cellular reprogramming therapies to restore cell types lost through disease or injury. Its MOGRIFY and epiMOGRIFY platforms use transcriptomic and epigenetic data to identify transcription-factor and growth-factor combinations for direct cell conversion and maintenance of cell identity. Programs target degenerative diseases, including ophthalmology, otology, and diabetes, with commercialization through therapy development, partnerships, and platform/IP.